TIDMAREC

RNS Number : 6673A

Arecor Therapeutics PLC

23 January 2024

Arecor Therapeutics plc

("Arecor" or the "Company")

ARECOR ANNOUNCES UPDATE ON INBRX-101

- Sanofi to acquire Inhibrx's AATD therapy INBRX-101, which incorporates a novel formulation developed under a license agreement using Arecor's Arestat (TM) technology, for up to $2.2 billion

- Terms of Arecor's license agreement are unchanged. Arecor remains entitled to further payments on achievement of certain development, regulatory and commercial milestones along with annual technology access fees post commercialisation

Cambridge, UK, 23 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, notes the news announced today from Inhibrx, Inc. (Nasdaq: INBX) and Sanofi (Nasdaq: SNY) that the companies have entered into a definitive agreement under which Sanofi will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD").

INBRX-101 incorporates a novel enhanced formulation developed by Arecor, using the Company's patented technology, Arestat(TM), under a license agreement entered into by Arecor and Inhibrx in December 2020. In November 2023 , Arecor announced that, under the terms of its license agreement, a milestone payment from Inhibrx had been triggered. The terms of the license agreement remain unchanged and, following the acquisition, Arecor remains entitled to further payments on the achievement of certain development, regulatory and commercial milestones along with annual technology access fees post commercialisation. The FDA has granted orphan-drug designation to INBRX-101 for the treatment of AATD and an initial read-out from the ongoing registration-enabling trial is expected to occur in late 2024.

Sarah Howell, Chief Executive Officer of Arecor, said: "Following on from the recent commercialisation of AT220, which is now royalty-bearing for Arecor, the acquisition of Inhibrx for INBRX-101 by Sanofi, announced today, is a further endorsement of the Arestat(TM) platform. Sanofi is a global pharmaceutical leader with a 30-year heritage in rare diseases and this acquisition highlights both the value of this novel therapy for patients and its future commercial potential. We believe they are well placed to complete the late-stage development of this novel medicine and, ultimately, bring it to patients in need. We congratulate the Inhibrx team and look forward to working with Inhibrx and Sanofi, as well as updating the market on future developments from this programme."

INBRX-101 is an optimized recombinant human AAT-Fc fusion protein, for treatment of patients with emphysema due to AATD. AATD is an underdiagnosed inherited orphan genetic disease that can cause serious lung disease in adults and/or liver disease at any age, affecting an estimated 100,000 patients in the United States. INBRX-101 has the potential to significantly reduce the frequency of annual infusions, eliminate lung decline from Alpha-1 Disease, and could significantly improve patient quality of life compared to the current standard of care.

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                  www.arecor.com 
 Dr Sarah Howell, Chief Executive         Tel: +44 (0) 1223 426060 
  Officer                                  Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer   Tel: +44 (0) 1223 426060 
                                           Email: info@arecor.com 
 
 Mo Noonan, Communications                Tel: +44 (0) 7876 444977 
                                           Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD       Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 ICR Consilium 
 Chris Gardner, David Daley, Lindsey      Tel: +44 (0) 20 3709 5700 
  Neville                                  Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDKZGZMVFVGDZM

(END) Dow Jones Newswires

January 23, 2024 11:58 ET (16:58 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Arecor Therapeutics Charts.
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Arecor Therapeutics Charts.